American Journal of Ophthalmology
Volume 143, Issue 4 , Pages 566-583.e2 , April 2007

An Optical Coherence Tomography-Guided, Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular Degeneration

  • Anne E. Fung

      Affiliations

    • Pacific Eye Associates, California Pacific Medical Center, San Francisco, California
    • ,
  • Geeta A. Lalwani

      Affiliations

    • Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
    • ,
  • Philip J. Rosenfeld

      Affiliations

    • Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
    • Corresponding Author InformationInquiries to Philip J. Rosenfeld, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, 900 N.W. 17th Street, Miami, FL 33136;
    • ,
  • Sander R. Dubovy

      Affiliations

    • Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
    • ,
  • Stephan Michels

      Affiliations

    • University Eye Hospital Vienna, Austria.
    • ,
  • William J. Feuer

      Affiliations

    • Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
    • ,
  • Carmen A. Puliafito

      Affiliations

    • Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
    • ,
  • Janet L. Davis

      Affiliations

    • Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
    • ,
  • Harry W. Flynn Jr

      Affiliations

    • Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida
    • ,
  • Maria Esquiabro

      Affiliations

    • Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida

,Accepted 13 January 2007.

References 

  1. Gragoudas ES, Adamis AP, Cunningham ET, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (Pegaptanib for neovascular age-related macular degeneration). N Engl J Med. 2004;351:2805–2816
  2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–1431
  3. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab vs verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–1444
  4. Preliminary results from a phase IIIb study showed patients with wet AMD treated with Lucentis quarterly experienced a 16-letter benefit over the control group at one year. [press release]. South San Francisco, California: Genentech; June 2, 2006. Available at: http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=9747. Accessed Date: August 26, 2006.
  5. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol. 1999;293:865–881
  6. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006;113:642;e1–e4
  7. Rosenfeld PJ, Heier JS, Hantsbarger G, et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:632;e1
  8. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials TAP report 1. Arch Ophthalmol. 1999;117:1329–1345

 See accompanying Editorial on page 679.

PII: S0002-9394(07)00068-2

doi: 10.1016/j.ajo.2007.01.028

American Journal of Ophthalmology
Volume 143, Issue 4 , Pages 566-583.e2 , April 2007

Article Tools

* Image Usage & Resolution